HC Wainwright Issues Pessimistic Forecast for EYPT Earnings

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) – Research analysts at HC Wainwright dropped their Q3 2026 EPS estimates for Eyepoint Pharmaceuticals in a research note issued to investors on Thursday, August 6th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings of ($0.60) per share for the quarter, down from their prior forecast of ($0.48). HC Wainwright currently has a “Buy” rating and a $27.00 price target on the stock. The consensus estimate for Eyepoint Pharmaceuticals’ current full-year earnings is ($3.45) per share. HC Wainwright also issued estimates for Eyepoint Pharmaceuticals’ Q4 2026 earnings at ($0.48) EPS, FY2026 earnings at ($3.15) EPS, Q1 2027 earnings at ($0.48) EPS, Q2 2027 earnings at ($0.46) EPS, Q3 2027 earnings at ($0.45) EPS, Q4 2027 earnings at ($0.45) EPS and FY2027 earnings at ($1.84) EPS.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last announced its earnings results on Wednesday, August 5th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.08). Eyepoint Pharmaceuticals had a negative net margin of 10,994.73% and a negative return on equity of 135.81%. The company had revenue of $0.51 million during the quarter, compared to the consensus estimate of $0.45 million.

Several other equities research analysts have also recently commented on EYPT. Royal Bank Of Canada dropped their target price on Eyepoint Pharmaceuticals from $39.00 to $37.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Chardan Capital reiterated a “buy” rating and set a $65.00 price target on shares of Eyepoint Pharmaceuticals in a research report on Friday. Cantor Fitzgerald boosted their price objective on Eyepoint Pharmaceuticals from $47.00 to $55.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. Stifel Nicolaus assumed coverage on Eyepoint Pharmaceuticals in a report on Thursday, July 16th. They issued a “buy” rating and a $40.00 price objective for the company. Finally, Guggenheim restated a “buy” rating and issued a $68.00 price objective on shares of Eyepoint Pharmaceuticals in a report on Wednesday, June 24th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $44.38.

Eyepoint Pharmaceuticals Trading Down 5.9%

Shares of NASDAQ:EYPT opened at $13.07 on Monday. The company has a 50 day moving average of $13.11 and a 200-day moving average of $13.75. The firm has a market cap of $1.13 billion, a P/E ratio of -3.49 and a beta of 1.76. Eyepoint Pharmaceuticals has a twelve month low of $9.65 and a twelve month high of $19.11.

Institutional Investors Weigh In On Eyepoint Pharmaceuticals

A number of large investors have recently made changes to their positions in the company. KBC Group NV acquired a new stake in Eyepoint Pharmaceuticals during the 1st quarter valued at $29,000. Mirae Asset Global Investments Co. Ltd. raised its position in Eyepoint Pharmaceuticals by 51.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,023 shares of the company’s stock valued at $74,000 after buying an additional 1,358 shares during the period. California State Teachers Retirement System lifted its stake in Eyepoint Pharmaceuticals by 20.6% in the 4th quarter. California State Teachers Retirement System now owns 4,654 shares of the company’s stock worth $85,000 after acquiring an additional 794 shares in the last quarter. Russell Investments Group Ltd. acquired a new stake in Eyepoint Pharmaceuticals during the 3rd quarter worth about $76,000. Finally, Persistent Asset Partners Ltd acquired a new stake in Eyepoint Pharmaceuticals during the 4th quarter worth about $98,000. Institutional investors and hedge funds own 99.41% of the company’s stock.

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.